🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🎥 #ASCO2025 In-Depth! Francois Duhoux & Elisa Agostinetto on DESTINY-Breast09: ✔️ +13 mo PFS (T-DXd + p) > THP ✔️ 21% d/c due to AEs ✔️ ILD risk noted ✔️ Target: aggressive HER2+ MBC 👀 Watch now bit.ly/4mLvOXR #MediMix #BreastCancer #MBC #Inavolisib #PI3Kinhibitor

🎥 #ASCO2025 In-Depth! Dr Evandro de Azambuja, MD, PhD & Dr Elisa Agostinetto on ASCENT-04: ✔️ SG + pembro: PFS 11.2 vs 7.8 mo ✔️ PD-L1+ mTNBC, 1L ✔️ Crossover allowed ✔️ New chemo-free option? 👀 Watch now bit.ly/4mLvOXR #MediMix #TNBC #PDL1

Register now and join on Thursday 26 June or on demand thereafter: us02web.zoom.us/webinar/regist… 🔹 Interactive, free & case-based webinar 🔹 International expert panel 🔹 Covering the latest #ASCO25 breast cancer data 🔹 Focused on the translation into clinical practice

Effect of pretreatment lab abnormalities on the time-to-treatment discontinuation and overall survival of metastatic breast cancer patients receiving CDK 4/6i, PI3Ki, and/or mTORi buff.ly/GbIlgzk Study aimed to address the underrepresentation of metastatic

What a way to finish the week🚨 TODAY THE BEST OF #Immunotherapy by our faculty John Haanen 🇳🇱Brought to you by our partners European Society of Surgical Oncology (ESSO) MASCC ESGO and SIOG in collaboration with GUARD Consortium Advanced Prostate Cancer Consensus Conference KidneyCAN & GU Cast | Urology podcast! Dra. María Natalia Gandur Quiroga

The OncoAlert🚨Newsletter Now Out !! Covering Jun 12-19, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… ✅Association of HRR Alterations With Outcomes in Metastatic Hormone-Sensitive Prostate Cancer ✅Comorbidity Burden and Effectiveness of

The OncoAlert newsletter is out! 📬 Register at oncoalert.m-pages.com/nhMpwe/oncoale…

Invitation from Dr. Véronique Diéras! Register here, it's free: us02web.zoom.us/webinar/regist… and join her for a 🧑‍💻 Case-based, interactive webinar 🧑‍⚕️ Covering the management of HER2+ metastatic #BreastCancer 🆕 Including the latest #ASCO25 data 🤝with Elisa Agostinetto,

🎥 #ASCO2025 Poster! SYNERGY (Dr Elisa Agostinetto): ✔️ No OS/PFS diff ✔️ ctDNA+ → worst outcomes ✔️ ctDNA clearance = better survival 👀 Watch now bit.ly/4mLvOXR #MediMix #TNBC #Biomarker

🎥 #ASCO2025 Poster! PAMBRACA (Dr Emma Zattarin & Dr Elisa Agostinetto): ✔️ Olaparib post-CDK4/6i = rwPFS 13 mo ✔️ Early use = more benefit ✔️ Real-world BRCA+ data 👀 Watch now bit.ly/4mLvOXR #MediMix #BreastCancer

🎥 #ASCO2025 Poster! Antonio Marra & Elisa Agostinetto: ✔️ BRCA2 → worst outcomes ✔️ 80% ineligible for PARP therapy 👀 Watch now bit.ly/4mLvOXR #MediMix #BreastCancer #BRCA

Our latest webinar on HER2+ metastatic #BreastCancer is now available on demand! 🆓Register for free at tinyurl.com/edhvcb28 to access this and other webinars! 🧑‍⚕️ With our international expert panel: Elisa Agostinetto, Nicolò Battisti, MD, Fatima Cardoso and Véronique Diéras 🆕

The OncoAlert newsletter is out! 📰 🏖️ Register at oncoalert.m-pages.com/nhMpwe/oncoale…

Diversity in clinical trials: Maghreb pts have younger age and more aggressive BC but similar survival outcomes doi.org/10.1016/j.clbc… Chiara Dauccia Véronique Debien Soraia Lobo-Martins Elisa Agostinetto Luca Arecco, MD Diogo Martins Branco

After the oral presentation at #ESMO24 by Eva Blondeaux, our last work from the BRCA BCY collaboration is now out in JNCI Breastfeeding after #breastcancer in patients with germline BRCA mutation🧬 is safe and does not ⬆️ recurrences OncoAlert academic.oup.com/jnci/advance-a…

Top Women Oncologists for Q2 2025, curated by LARVOL CLIN. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights | Sharlene Gill, MD, MPH, MBA, FASCO | Aya Mohamed | MSc, MD 🎗 |

Breastfeeding after breast cancer in young BRCAcarriers academic.oup.com/jnci/advance-a… This international retrospective cohort study evaluated the safety of breastfeeding after breast cancer in women with germline BRCA🧬 pathogenic or likely pathogenic variants. Among 474 BRCA

The OncoAlert VJ Oncology JOURNAL CLUB This week we have the pleasure to bring you Icro Meattini 🇮🇹of the University of Florence Discussing: Multimodal De-Escalation Strategies in Early Breast Cancer on the ASCO Educational Book Direct Link to Publication

Get insights on the latest evidence in HER2+ metastatic #BreastCancer with our 🆓 on-demand webinar! ➡️Register here: tinyurl.com/edhvcb28 🧑‍⚕️ Featuring Elisa Agostinetto, Nicolò Battisti, MD, Fatima Cardoso and Véronique Diéras 💡 Case-based, practical takeaways you can apply now

The last OncoAlert newsletter is out📩 today featuring the BRCA BCY paper on breastfeeding in BRCA-mut #breastcancer! Register at: oncoalert360.com